Semaglutide is a non stimulant, non habit forming FDA approved medication used for chronic weight management in adults with obesity (BMI of 30>) or overweight (BMI of 27>) with at least one health condition (high blood pressure, type 2 diabetes, or high cholesterol).
What is Semaglutide?
Semaglutide is a drug that mimics a naturally occurring hormone called glucagon-like peptide-1 (GLP-1). It works on the same appetite receptors in the brain that improve your metabolic function, and slows the emptying of your stomach leading to feelings of fullness for longer, reducing hunger and cravings, in addition to improved eating control.
Semaglutide is clinically proven to be most effective for long term results when combined with a reduced calorie diet and increased physical activity. This weight loss medication is a subcutaneous injection administered once weekly in the abdomen, thigh or upper arm with or without food. The starting dose is 0.25mg for one month (4 weekly injections) and is designed to gradually increase the dosage over 16 to 20 weeks (typically every month) to minimize gastrointestinal side effects.
The available strengths are 0.25mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg.
After you increase to 2.4 mg, you have completed the escalation process, and will continue to just use the 2.4 mg dose for as long as you take the medication.
FDA approval came after a robust series of placebo-controlled trials with thousands of participants of varying ages. In one of the most successful trials, participants had an average initial body weight of 231 pounds and a BMI of 38. People who received semaglutide lost an average of 14.9% of their initial body weight (a loss of about 34 pounds) during the 68-week trial. Those who received a placebo lost only 2.4% of their body weight.